Sk Chemicals Co., Ltd.

Ewha University-Industry Collaboration Foundation

In2gen Co., Ltd.

Sunkyong Industries Co., Ltd.

Sunkyong Industries Ltd.

Dae-Kee Kim

Hun-Taek Kim

Chul-Yong Park

Jin Young Choi

Jae Won Choi

Chenghua Jin

Yhun Yhong Sheen

In-Young Song

Yung-Jue Bang

Sreenu Domalapally

Sudhakar Rao Kota

Krishnaiah Maddeboina

Subrahmanyam Vura Bala

Yong-Kook Kim

Jae-Sun Kim

Ju Young Lee

Nam Kyu Lee

Je Ho Ryu

Guang-Jin Im

Key Hyup Kim

Tae Kon Kim

Jong-Wan Kim

Joon Hun Choi

Young Jae An

Ganghyeok Kim

Jongsik Gam

Jong-Il Ryu

Suk Ho Lee

Myoung-Soon Park

Il-Sang Cho

Jinsoo Lim

Nam Ho Kim

Young-Woo Kim

Jung-Woo Seo

Ho Soon Lee

Hun T Kim

Yong B Cho

Do Hyun Ryu

Joo H Tai

Namkyu Lee

Domalapally Sreenu

Won-Son Choi

Jin-Young Choi

Nam-Ho Kim

Jin-Wook Jang

Young-Jue Bang

Junwon Lee

Vura Bala Subrahmanyam

Maddeboina Krishnaiah

Kota Sudhakar Rao

Hoon Cha

This invention relates to use of inhibitors of the transforming growth factor-&#x3b2; (TGF-&#x3b2;) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.

Methods of treating fibrosis, cancer and vascular injuries

This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-&#x3b2; (TGF-&#x3b2;) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.

2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors

Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.

Process for producing and purifying factor VIII and its derivatives

A compound of the formula: Wherein A, A, X, Rand R3 are as defined herein, or a composition containing the same, which compound is useful in treating renal-, liver- or pulmonary fibrosis.

2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

&#x3b1;,&#x3b2;-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors

Compounds of the formula: wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-&#x3b2; and/or activin signaling pathway in mammals.

The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.

Factor VIII polypeptide

The invention relates to a series of pyrrolopyrimidinone derivatives of the formula ():

Pyrrolopyrimidinone derivatives, process of preparation and use

Pyrimidine acyclonucleoside derivatives

Disclosed herein are novel platinum(II) complexes having a potent anti-tumor activity which are represented by the formula (1), ##STR1## wherein R.sub.1 and R.sub.2, which may be the same or different, are a hydrogen atom or a C.sub.1-4 alkyl group, respectively, or jointly form a cycloalkane group together with the carbon atom attached thereto; two Xs jointly form a group represented by formula (a) or (b) wherein, R.sub.3 is a hydrogen atom or a methyl group; R.sub.4 and R.sub.5, which may be the same or different, are a hydrogen atom or a C.sub.1-4 alkyl group, respectively, or jointly form a cyclobutane together with the carbon thereto; and the absolute configurations at the respective chiral centers in the 4,5-bis(aminomethyl)-1,3-dioxolane moiety are (4R,5R) or (4S,5S); processes for the preparing the same; and their use for treating animal or human cancer. Further, disclosed herein are novel intermediates useful for the preparation of the platinum(II) complexes and processes for preparing said intermediates.

Platinum(II) complex and processes for preparing the same

Growing community of inventors

Seoul, South Korea

Dae-Kee Kim